Seguimento de 48 semanas de um estudo randomizado | Pegcetacoplan vs. eculizumabe em pacientes com hemoglobinúria paroxística noturna.

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

Estudo original: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine

Comentário no Twitter (fio – clique para saber mais)

NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X

— The Lancet Haematology (@TheLancetHaem) September 1, 2022